Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone reveals a focused interest in mutations like E484K and the implications for vaccine effectiveness, as shown in posts referencing the emergence of new variants and vaccine responses, which reflects eagerness to understand and respond to evolving threats. The use of words like 'threat,' 'update,' and 'effectiveness' demonstrate serious consideration of the article's significance and potential influence on public health strategies.
Many discussions express support or acknowledgment of the findings, indicating general agreement, though some note limitations or skepticism.
Discussions show moderate curiosity, with mentions of vaccine effectiveness and mutation implications reflecting genuine scientific interest or concern.
Posts often reference specific mutations like E484K and include technical details or calls for updates, indicating active engagement.
The topics discussed highlight the relevance of the research to ongoing vaccine efficacy debates and mutation concerns, suggesting a moderate to high perceived impact.
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies "E484K emergence on a B.1.1.7 background represents a threat to the #vaccine BNT162b" #vaccination #immunity #coronavirus #covid19 https://t.co/DOv0c5fbGR https://t.co/ymtMq9lQPQ
New initial report (https://t.co/yoHBRNWplr) re effectiveness of Pfizer vaccine BNT162b2 vax on mutated forms of #COVID19 (technically Sars-CoV-2, the actual virus): boils down to "seems to work ok."
RT @IndelibleFink: New initial report (https://t.co/yoHBRNWplr) re effectiveness of Pfizer vaccine BNT162b2 vax on mutated forms of #COVID1…
Update: SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies https://t.co/lWJ1vyNPce read/write/request review https://t.co/C4shXKM0FN #coronavirus #COVID19
The preprint “SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-eli…” (https://t.co/s9T4JBewuO) has been reviewed by automated tools, find results here: https://t.co/Nz5a3XgMFx. We detected 1 of 5 rigor criteria, 0 resources, and no limitations statement.
New article: SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies https://t.co/Ty9Qhgjq7L #coronavirus #COVID19 #2019ncov https://t.co/hcRVxUAICf
This week we will analyze the impact of SARS-CoV-2 spike proteins on the alternative complement pathway. The discussion includes evidence that inhibiting factor D could mitigate complications in COVID-19, highlighting a…
This video examines how T cells react to SARS-CoV-2 infection in 99 recovered patients. Researchers investigate a comprehensive range of peptides to understand T cell immunodominance and antibody responses, enhancing…
Trend up+1: Collier DA, ..., Gupta RK (medRxiv) __SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies__ https://t.co/YORys7lDy3
The preprint “SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-eli…” (https://t.co/s9T4JBewuO) has been reviewed by automated tools, find results here: https://t.co/Nz5a3XgMFx. We detected 1 of 5 rigor criteria, 0 resources, and no limitations statement.
Trend new: Collier DA, ..., Gupta RK (medRxiv) __SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies__ https://t.co/YORys7lDy3
New article: SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies https://t.co/Ty9Qhgjq7L #coronavirus #COVID19 #2019ncov https://t.co/hcRVxUAICf
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies 15/02/21 [Preprint] / Dami A. Collier et al // medRXiv https://t.co/aDF47johQp https://t.co/yNGabKJpIN
RT @Thomas_Wilckens: SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies "E484K emergence on a…
RT @majohanss: Update: SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies https://t.co/lWJ1vyN…
Update: SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies https://t.co/lWJ1vyNPce read/write/request review https://t.co/C4shXKM0FN #coronavirus #COVID19
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies "E484K emergence on a B.1.1.7 background represents a threat to the #vaccine BNT162b" #vaccination #immunity #coronavirus #covid19 https://t.co/DOv0c5fbGR https://t.co/ymtMq9lQPQ
RT @IndelibleFink: New initial report (https://t.co/yoHBRNWplr) re effectiveness of Pfizer vaccine BNT162b2 vax on mutated forms of #COVID1…
New initial report (https://t.co/yoHBRNWplr) re effectiveness of Pfizer vaccine BNT162b2 vax on mutated forms of #COVID19 (technically Sars-CoV-2, the actual virus): boils down to "seems to work ok."